Sonye K. Danoff, MD, PhD
Associate Professor of Medicine
Co-Director, Johns Hopkins ILD/IPF Program
Johns Hopkins Myositis Center
ADDITIONAL CONTENT DEVELOPMENT FACULTY:
Imre Noth, MD
Chief, Division of Pulmonary and Critical Care Medicine
Dudley F. Rochester
Endowed Professor Of Medicine
University of Virginia
Mary E. Strek, MD
Professor of Medicine
Director, University of Chicago
Interstitial Lung Disease Program
Chair, Pulmonary Fibrosis Foundation
Clinical Care Network Registry Ancillary Studies Committee
Interstitial lung disease (ILD) comprises more than 130 distinct lung disorders. Some forms of ILD, including connective tissue disease-associated ILD (CTD-ILD), chronic hypersensitivity pneumonitis (CHP), and fibrosing types of ILD such as fibrotic nonspecific interstitial pneumonia (fNSIP), follow a particularly aggressive course. This activity will address the timely identification and treatment of these progressive phenotypes.
Physicians, nurse practitioners (NPs), and physician assistant (PAs) specializing in pulmonology, radiology, pathology, rheumatology, or primary care/internal medicine.
Upon completion of this educational activity, the participant should be able to:
- Identify and monitor patients who are at increased risk for ILD with a progressive phenotype.
- Describe the pathophysiology of ILD with a progressive phenotype.
- In patients at risk for having a progressive phenotype, recognize the signs and symptoms of ILD.
- Develop a management strategy for patients with ILD with a progressive phenotype.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Danoff has disclosed the following:
Grant/research support: Boehringer Ingelheim, Bristol-Myers Squibb
Consultant: Boehringer Ingelheim, Galapagos NV, Trevi Therapeutics
Dr. Noth has disclosed the following:
Consultant: Boehringer Ingelheim, Roche/Genentech, Immuneworks
Speakers bureau: Boehringer Ingelheim
Dr. Strek has disclosed the following:
Grant/research support: Boehringer Ingelheim, Novartis
Consultant: Boehringer Ingelheim
Speakers bureau: Boehringer Ingelheim
Penn State staff involved in the development and review of this activity have nothing to disclose.
MCM Education staff involved in the development and review of this activity have nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6321-19-T.
Commercial Support Statements
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.